Syneron Medical strengthens senior management
Philippe A. Schaison is joining as CEO of Syneron Candela North America and Global Executive Vice President Strategy and Business Development.
Dr. Schaison is joining Syneron from Allergan plc, where he served as President of the U.S. Aesthetic and Dermatology business since 2013, with responsibility for Allergan's top aesthetic brands, including Botox, Juvaderm, Skin Medica, and other leading brands.
Prior to Allergan, Dr. Schaison served in leadership roles of several aesthetic businesses, including Clarins, Johnson & Johnson where he served as VP of Global Skin Care, and L'Oreal.
Dr. Schaison received a Master of Business Administration in marketing from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy from the University Of Paris V.
Paul Little is joining as Global Chief Operating Officer.
Mr. Little brings over 30 years of experience in finance, business strategy and operations roles, spanning pharmaceutical, medical device, consumer packaged goods and public accounting industries.
Most recently, he served as the Vice President, Finance and Head of Commercial operations of Allergan Medical Aesthetics. He began his career in public accounting at KPMG.
Mr. Little earned a BA in Business Economics from the University of California, Santa Barbara.
Yariv Matzliach is joining as Executive Vice President, Distribution Channels.
Dr. Matzliach is a co-founder of Alma Lasers, a global developer, manufacturer and provider of cosmetic laser solutions and medical lasers where he served as President from 2004 to 2011.
Prior to Alma Lasers, Dr. Matzliach served in sales and marketing positions at several medical companies.
He received a Doctor of Dental Surgery at UNAM in Mexico City and completed the Executive Business Administration course at Elscint in Paris. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST
Visa Q2 GAAP net income $430 million Earnings